Immuneering
IMRX
95 hedge funds and large institutions have $154M invested in Immuneering in 2026 Q1 according to their latest regulatory filings, with 30 funds opening new positions, 27 increasing their positions, 22 reducing their positions, and 17 closing their positions.
76% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 17
23% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 22
12% more funds holding
Funds holding: 85 → 95 (+10)
3.78% less ownership
Funds ownership: 49.11% → 45.33% (-3.8%)
26% less capital invested
Capital invested by funds: $209M → $154M (-$54.4M)
33% less call options, than puts
Call options by funds: $962K | Put options by funds: $1.43M
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$6.59M |
| 2 |
Millennium Management
New York
|
+$5.39M |
| 3 |
SF
Summit Financial
Parsippany,
New Jersey
|
+$1.93M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$1.83M |
| 5 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
+$1.37M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Empery Asset Management
New York
|
-$17.6M |
| 2 |
State Street
Boston,
Massachusetts
|
-$10.9M |
| 3 |
BOCH
Blue Owl Capital Holdings
New York
|
-$4.38M |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$1.09M |
| 5 |
Morgan Stanley
New York
|
-$992K |
IMRX Hedge Fund Activity: Q1 2026 in Review
95 of the 8,191 institutional investors tracked by Wall St. Rank reported a position in Immuneering (IMRX) for Q1 2026, worth a combined $154M — down 26% from $209M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new IMRX positions and 17 closed out — a net gain of 13 holders — while 27 added to existing stakes and 22 trimmed.
The largest buyer was Marshall Wace, adding an estimated $6.59M. The largest seller was Empery Asset Management, exiting entirely with an estimated $17.6M sold.
- 95 institutional investors held Immuneering (IMRX) as of Q1 2026, up from 85 in Q4 2025.
- Funds reported $154M of Immuneering stock for Q1 2026, down 26% quarter-over-quarter.
- 30 funds opened new Immuneering positions in Q1 2026 and 17 closed out, a net change of +13 holders.
- The largest Immuneering buyer in Q1 2026 was Marshall Wace, an estimated $6.59M added.
- The largest Immuneering seller in Q1 2026 was Empery Asset Management, an estimated $17.6M sold.
Based on aggregated 13F filings for Q1 2026.